Nevro Corp. (NYSE:NVRO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Angie McCabe - VP, IR & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Robbie Marcus - JPMorgan Brandon Vazquez - William Blair Anthony Petrone - Mizuho Bill Plovanic - Canaccord David Rescott - Baird Operator Good afternoon. My name is Mark, and I will be your conference operator ...

Nevro (NVRO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.75%. A quarter ago, it was expected that this maker of an electrical implant that treats leg and back pain would post a loss of $1.02 per share when it actually produced a loss of $0.70, delivering a surprise of 31.37%. Over the ...

IIIIIIII neving Second-Quarter 2024 Earnings Conference Call August 6, 2024 ©2024 Nevro Corp. All rights reserved. S000000 Forward-Looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the current beliefs and expectations of the company's management, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our revised full-year 2024 financial guidance and our third quarter 2024 financi ...

Exhibit 99.1 Nevro Reports Second-Quarter 2024 Financial Results Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, California – August 6, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share NVRO The New York Stock Exchange FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro ...

Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, toda ...

REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. For those parties that do not have internet access, th ...

Internet Posting of Information Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 115,000 pat ...

It has been about a month since the last earnings report for Nevro (NVRO) . Shares have lost about 8.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Nevro due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Nevro's Q1 Earnings and Sales Top Estimates, Margins Up ...

Nevro Corp. (NVRO) is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid first-quarter 2024 performance and continued strength in its flagship Senza platform, is expected to contribute further. However, stiff competition and dependence on third-party payors persist. In the past year, this Zacks Rank #3 (Hold) stock has lost 66.1% against the industry's 6.1% growth. The S&P 500 rallied 23.5% in the same time frame. The renowned glo ...